MARKET

ARMP

ARMP

Armata Pharmaceuticals Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

3.910
+0.065
+1.69%
Closed 16:00 08/05 EDT
OPEN
3.833
PREV CLOSE
3.845
HIGH
3.910
LOW
3.812
VOLUME
6.58K
TURNOVER
--
52 WEEK HIGH
6.92
52 WEEK LOW
2.520
MARKET CAP
72.90M
P/E (TTM)
-1.7348
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARMP stock price target is 7.75 with a high estimate of 9.00 and a low estimate of 5.00.

EPS

ARMP News

More
Here's Why We're Watching Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Situation
Simply Wall St. · 06/30 11:05
Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections
PR Newswire · 06/17 12:30
Armata Pharmaceuticals Announces $15M Award From The US Department Of Defense For Development Of Bacteriophage Therapy To Treat S. Aureus Bacteremia Infections
MARINA DEL REY, Calif., June 17, 2020 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage
Benzinga · 06/17 11:32
H.C. Wainwright Reiterates Buy on Armata Pharmaceuticals, Lowers Price Target to $5
H.C. Wainwright analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and lowers the price target from $9 to $5.
Benzinga · 05/15 11:15
Armata Pharmaceuticals EPS misses by $0.18
Armata Pharmaceuticals (NYSEMKT:ARMP): Q1 GAAP EPS of -$0.49 misses by $0.18. Cash, cash equivalents and restricted cash of $24.81M. Press Release
seekingalpha · 05/15 01:30
Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update
PR Newswire · 05/14 21:05
Armata Pharmaceuticals (ARMP) Investor Presentation - Slideshow
Seeking Alpha - Article · 05/08 16:04
Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector
PR Newswire · 04/28 13:00

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About ARMP

Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
More

Webull offers kinds of Armata Pharmaceuticals Inc stock information, including AMEX:ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.